Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
01 Maio 2024 - 9:00AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company")
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare and difficult-to-treat
diseases today announced that Richard J. Daly, President and
CEO of Catalyst, along with other members of Catalyst's management
team, will participate at the upcoming BofA Securities Health Care
Conference 2024 on Tuesday, May 14, 2024, at the Encore Hotel, Las
Vegas, Nevada.
Presentation Details:
Date: |
|
Tuesday, May
14, 2024 |
Time: |
|
5:00 pm PT |
|
The webcast will be available under the
Investors section on the Company's website, www.catalystpharma.com,
and a replay will be available for at least 14 days.
About Catalyst Pharmaceuticals, Inc.
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare and difficult-to-treat
diseases. Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment
of Lambert-Eaton myasthenic syndrome ("LEMS") for adults
and for children ages six to seventeen. In January 2023,
Catalyst acquired the U.S. commercial rights to FYCOMPA®
(perampanel) CIII, a prescription medicine approved in people with
epilepsy aged four and older alone or with other medicines to treat
partial-onset seizures with or without secondarily generalized
seizures and with other medicines to treat primary generalized
tonic-clonic seizures for people with epilepsy aged 12 and older.
Further, Canada's national healthcare regulatory
agency, Health Canada, has approved the use of FIRDAPSE for
the treatment of adult patients in Canada with LEMS.
On July 18, 2023, Catalyst acquired an exclusive license
for North America for AGAMREE® (vamorolone) oral
suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne
Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and
Fast Track designations and was approved by the FDA for
commercialization in the U.S. on October 26, 2023.
AGAMREE became commercially available by prescription in the U.S.
on March 13, 2024.
For more information about Catalyst
Pharmaceuticals, Inc., please visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, please visit www.firdapse.com. For
Full Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE®, please visit www.agamree.com.
Forward-Looking Statements
This press release contains forward-looking
statements, as that term is defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially
from forecasted results. A number of factors, including those
factors described in Catalyst's Annual Report on Form 10-K for the
fiscal year 2023 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely
affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024